Key facts
- RayThera’s last known valuation is $186.0M (Apr 2025).
- It has raised $110.0M; the latest was Early Stage VC ($110.0M) in Apr 2025.
- Notable investors include OrbiMed, Foresite Capital, TTM Capital (Shanghai).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for RayThera
- ·The full record, as it builds
Funding rounds
No funding rounds for RayThera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RayThera
Operator of a small molecule drug discovery company intended to focus on building an immunology pipeline. The company specializes in developing breakthrough small-molecule therapies for critical unmet needs in immunology with proven expertise, adaptable approaches, and a focus on transformative therapies, enabling doctors to deliver solutions that are poised to transform patient care.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Website
- raythera.com/
- Ownership
- Privately Held (backing)
RayThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RayThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RayThera in its N-PORT filings yet. We sweep new filings monthly.